A Single-Center, Randomized, Open-Label, Parallel Arm Study of Daily Oral LUM-201 in Naive-to-Treatment, Prepubertal Children With Idiopathic Pediatric Growth Hormone Deficiency (PGHD)
Latest Information Update: 05 Nov 2024
At a glance
- Drugs Ibutamoren (Primary)
- Indications Somatotropin deficiency
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms OraGrowtH212
- Sponsors Lumos Pharma
- 30 Oct 2024 According to a Lumos Pharma media release, updated analyses of data from the Company's Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK.
- 05 Sep 2024 According to a Lumos pharma Media Release, company announced that an updated analysis of data from this trials has been accepted for presentation at the XXXI Meeting of the Latin American Society of Paediatric Endocrinology, to be held September 11-14, 2024 in Chile.
- 04 Jun 2024 According to a Lumos pharma Media Release, the company announced details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), held in Boston, MA, June 1-4, 2024. The posters were presented in parallel sessions on Monday June 3, 2024.